Hostname: page-component-76fb5796d-zzh7m Total loading time: 0 Render date: 2024-04-28T09:57:44.378Z Has data issue: false hasContentIssue false
  • English
  • Français

Seroepidemiology of HTLV-I in relation to that of HIV-1 in the Gauteng region, South Africa, using dried blood spots on filter papers

Published online by Cambridge University Press:  15 May 2009

M. B. Taylor ,
S. P. Parker ,
H. H. Crewe-Brown ,
J. McIntyre  and
W. D. Cubitt
M. B. Taylor
Affiliation:
Department of Medical Virology, Institute of Pathology, University of Pretoria, PO Box 2034, Pretoria, South Africa
S. P. Parker
Affiliation:
Department of Virology, Institute of Child Health, London, United Kingdom
H. H. Crewe-Brown
Affiliation:
Department of Clinical Microbiology, South African Institute for Medical Research and The University of the Witwatersrand, Johannesburg, South Africa
J. McIntyre
Affiliation:
Department of Obstetrics and Gynaecology, Baragwanath Hospital and The University of the Witwatersrand, Bertsham, South Africa
W. D. Cubitt
Affiliation:
Department of Virology, Institute of Child Health, London, United Kingdom
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The seroprevalence of human T-lymphotropic virus type I (HTLV-I), in relation to that of human immunodeficiency virus type 1 (HIV-1), was determined in a comparative unlinked anonymous antenatal and neonatal (for indirect measurement of maternal antibodies) serosurvey in the Gauteng region of South Africa, using dried blood spots (DBS) and modified particle agglutination assays. Samples were confirmed to be antibody positive by western blot. A total of 2582 DBS collected during 1993 and 1994 from subjects of African, European and coloured origin were tested. Ten were confirmed as positive for HTLV-I and 128 for HIV-1. No antibodies to HTLV-I or HIV-l were demonstrated in the 221 women of European and coloured origin who were screened. The HTLV-I seroprevalence rate in subjects of African origin appeared to increase from 0% in 1993 to 0·49% in 1994, while HIV-1 seroprevalence rates of 5·2% and 5·4% were recorded for 1993 and 1994 respectively. No significant differences in HTLV-I and HIV-1 seroprevalence rates were noted for the two areas investigated. These results indicate that HTLV-I should be included in infection control programs, and provide baseline data for monitoring the possible spread of HTLV-I in the heterosexual population in this region.

Type
Research Article
Information
Epidemiology & Infection , Volume 117 , Issue 2 , October 1996 , pp. 343 - 348
Copyright
Copyright © Cambridge University Press 1996

References

1.Hinuma, Y, Nagata, K, Hanaoka, M, et al. Adult T-celI leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981; 78: 6476–80.CrossRefGoogle Scholar
2.Yoshida, M, Miyoshi, I, Hinuma, Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982; 79: 2031–5.CrossRefGoogle ScholarPubMed
3.Gessain, A, Vernant, JC, Maurs, L, et al. Antibodies to human T-lymphotropic virus type 1 in patients with tropical spastic paraparesis. Lancet 1985; ii: 407–9.CrossRefGoogle Scholar
4.Osame, M, Usuku, K, Izumo, S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; 1: 1031–2.CrossRefGoogle ScholarPubMed
5.Osame, M, Matsumoto, M, Usuku, K et al. Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type 1 and adult T-cell leukemia-like cells. Ann Neurol 1987; 21: 117–22.CrossRefGoogle Scholar
6.Mochizuki, M, Watanabe, T, Yamaguchi, K, et al. HTLV- 1 uveitis: a distinct clinical entity. Jpn J Cancer Res 1992; 83: 236–9.CrossRefGoogle ScholarPubMed
7.LaGrenade, L, Hanchard, B, Fletcher, V, Cranston, B, Blattner, W. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet 1990; 336: 1345–7.Google ScholarPubMed
8.Centers for Disease Control and Prevention and the U.S.P.H.S. Working Group. Guidelines for counseling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II). Ann.Int Med 1993; 118: 448–54.CrossRefGoogle Scholar
9.Tajima, KThe T- and B-cell Malignancy Study Group and Co-authors. The 4th nation-wide study of adult Tcell leukemia/lymphoma (ATL) in Japan: Estimates of risk of ATL and its geographic and clinical features. Int J Cancer 1990; 45: 237–43.CrossRefGoogle Scholar
10.Yamaguchi, K. Human T-lymphotropic virus type 1 in Japan. Lancet 1994; 343: 213–6.CrossRefGoogle ScholarPubMed
11.Blattner, WA, Blayney, DW, Robert-Guroff, M, et al. The human type-C retrovirus, HTLV, in blacks from the Caribbean, and relationship to adult T-cell leukemia/lymphoma. Int J Cancer 1982; 30: 257–64.CrossRefGoogle ScholarPubMed
12.Saxinger, W, Blattner, WA, Levine, PH, et al. Human Tcell leukemia virus (HTLV-I) antibodies in Africa. Science 1984; 225: 1473–6.CrossRefGoogle ScholarPubMed
13.De Thé, G, Gessain, A, Gazzolo, L, et al. Comparative seroepidemiology of HTLV-I and HTLV-II in the French West Indies and some African countries. Cancer Res 1985; 45: 4633s–6s.Google Scholar
14.Jeannel, D, Garin, B, Kazadi, K, Singa, L, de Thé, G. The risk of tropical spastic paraparesis differs according to ethnic group among HTLV-I carriers in Inongo, Zaïre. J AIDS; 6: 840–4.Google Scholar
15.Bhigjee, AI, Vinsen, C, Windsor, IM, Gouws, E, Bill, PLA, Tait, D. Prevalence and transmission of HTLV-I infection in Natal/Kwazulu. S Afr Med J 1993; 83: 665–7.Google ScholarPubMed
16.Garin, B, Gosselin, S, de Thé, G, Gessain, A. HTLV-I/II infection in a high endemic area of Zaire, Central Africa: Comparative evaluation of serology, PCR, and significance of indeterminate western blot pattern. J Med Virol 1994; 44: 104–9.CrossRefGoogle Scholar
17.Blayney, DW, Blattner, WA, Robert-Guroff, M, et al. The human T-cell leukemia-lymphoma virus (HTLV) in the southeastern United States. JAMA 1983; 250: 1048–52.CrossRefGoogle ScholarPubMed
18.Greaves, MF, Verbi, W, Tilley, R, et al. Human T-cell leukaemia virus (HTLV) in the United Kingdom. Int J Cancer 1984; 33: 795–806.CrossRefGoogle ScholarPubMed
19.Nightingale, S, Orton, D, Ratcliffe, D, Skidmore, S, Tosswill, J, Desselberger, U. Antenatal survey for the seroprevalence of HTLV-I infections in the West Midlands, England. Epidemiol Infect 1993; 110: 379–87.CrossRefGoogle ScholarPubMed
20.Bhigjee, AI, Kelbe, C, Haribhai, HC, et al. Myelopathy associated with human T cell lymphotropic virus type I (HTLV-I) in Natal, South Africa. A clinical and investigative study in 24 patients. Brain 1990; 113: 1307–20.CrossRefGoogle ScholarPubMed
21.Joubert, J, van As, AD, Lecatsas, G, Bos, P. Human Tlymphotropic virus type I-associated myelopathy. A case report. S Afr Med J 1991; 80: 592–3.Google ScholarPubMed
22.Jogessar, VB, de Bruyn, CC, Bhigjee, Al, Naicker, VL, Bill, PLA, Tait, D. Adult T-cell leukaemia/lymphoma associated with HTLV-I in Natal. S Afr Med J 1992; 81: 528–9.Google ScholarPubMed
23.Patel, M, Stevens, W, Crewe-Brown, HH, et al. Adult Tcell leukaemia/lymphoma: A case report. South Afr J Epidemiol Infect 1995; 10: 6–7.Google Scholar
24.Becker, WB, Becker, MLB, Homma, T, Brede, HD, Kurth, R. Serum antibodies to human T-cell leukaemia virus type I in different ethnic groups and in non-human primates in South Africa. S Afr Med J 1985; 67: 445–9.Google ScholarPubMed
25.Botha, MC, Jones, M, de Klerk, WA, Yamamoto, N. Distribution and possible spread of human T-cell Ieukaemia virus type I in human communities in the northern and eastern Transvaal. S. Afr Med J 1985; 67: 668–71.Google Scholar
26.Lecatsas, G, Joubert, JJ, Schutte, CHJ, Taylor, MB, Swanevelder, C. HTLV-I seropositivity in East Caprivi, SWA/Namibia. S Afr Med J 1988; 74: 643–4.Google ScholarPubMed
27.Neill, AGS, Fernandes-Costa, FJTD. Anti HTLV-I in blood donors in Natal. S Afr Med J 1990; 78: 376.Google ScholarPubMed
28.Taylor, MB, Janse van Rensburg, E, Swanevelder, C, Carlier, ND, Glatthaar, E. HIV and HTLV-I survey in Venda. S Afr Med J 1992; 81: 485.Google ScholarPubMed
29.Bhigjee, Al, Thaler, D, Madurai, S, Gouws, E, Bill, PLA. Seroprevalence of HTLV-I in Natal/KwaZulu. S Afr Med J 1994; 84: 368.Google ScholarPubMed
30.Maaga, S, Steele, AD, Bos, P, Lecatsas, G. HTLV-I infection in Bushmen at Schmidtsdrift. South Afr J Epidemiol Infect 1994; 9: 67–8.Google Scholar
31.Maaga, S, Steele, AD, Aspinall, S, Lecatsas, G. A seroepidemiological survey of HTLV-l and -II in STD clinic attendees and a healthy population group in Gauteng, South Africa. South Afr J Epidemiol Infect 1995; 10: 56–9.Google Scholar
32.Van der Ryst, E, Smith, MS. A high seroprevalence of HTLV-I antibodies in HIV-l seropositive patients with neurologic disease. South Afr J Epidemiol Infect 1994; 9: 20–3.Google Scholar
33.Ades, AE, Parker, S, Berry, T. et al. Prevalence of maternal HIV- 1 infection in Thames Regions: results from anonymous unlinked neonatal testing. Lancet 1991; 337: 1562–5.CrossRefGoogle ScholarPubMed
34.Department of Health. National HIV surveys in South Africa. Epidemiol Comments 1994; 21: 229.Google Scholar
35.Department of Health. The New South Africa. Epidemiol Comments 1994; 21: 94–7.Google Scholar
36.Department of Health. Fifth national HIV survey in women attending antenatal clinics of the public health services in South Africa. Epidemiol Comments 1995; 22: 90–100.Google Scholar
37.Crewe-Brown, HH, Modi, G, Khoosal, M. et al. Symptomatic HTLV-I infection at Baragwanath Hospital, South Africa. Prague, Czeck Republic: Abstracts of the 6th International Congress for Infectious Diseases, 1994: 221.Google Scholar
38.Peckham, CS, Tedder, RS, Briggs, M. et al. Prevalence of maternal HIV infection based on unlinked anonymous testing of newborn babies. Lancet 1990; 335: 516–9.CrossRefGoogle ScholarPubMed
39.Parker, SP, Taylor, MB, Ades, AE, Cubitt, WD, Peckham, C. Detection and confirmation of HTLV-I specific antibodies in dried blood spots for epidemiological studies. J Clin Pathol 1995; 48: 904–7.CrossRefGoogle Scholar
40.Centers for Disease Control. Interpretation and use of the western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR 1989; 38 (No. S-7): 1–7.Google Scholar
41.Noda, S, Eizuru, Y, Minamishima, Y, Ikenoue, T, Mori, N. Detection of human T-cell lymphotropic virus type 1 infection by the polymerase chain reaction using dried blood specimens on filter papers. J Virol Methods 1993; 43: 111–22.CrossRefGoogle ScholarPubMed
42.Yourno, J. Direct polymerase chain reaction for detection of human immunodeficiency virus in blood spot residues on filter paper after elution of antibodies: an adjunct to serological surveys for estimating vertical transmission rates among human immunodeficiency virus antibody-positive newborns. J Clin Microbiol 1983; 31:1364–7.CrossRefGoogle Scholar
43.Kalyanaraman, VS, Sarngadharan, MG, Robert-Guroff, M, Miyoshi, I, Golde, D, Gallo, RC. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1992; 18: 571–3.Google Scholar
44.Goubau, P. Desmyter, J, Swanson, P. et al. Detection of HTLV-I and HTL V-II infection in Africans using type- specific envelope peptides. J Med Virol 1993; 39: 28–32.CrossRefGoogle Scholar
45.Van der Riet, FdeStJ, Allan, BR, Hesseling, PB. Antibodies to human T-cell leukaemia virus protein p24 in healthy and diseased persons in SWA/Namibia. S Afr Med J 1984; 66: 515–6.Google Scholar
46.Becker, WB, Botha, MC, Engelbrecht, S, Becker, MLB. Isolation of human T-lymphotropic virus type I (HTLV-I) from a black South African with Kaposi's sarcoma. S Afr Med J 1988; 73: 481–3.Google Scholar